Novavax (NVAX) Change in Receivables (2010 - 2016)
Novavax (NVAX) recorded quarterly Change in Receivables of -$1.7 million in Q3 2016, down 6500.0% quarter-over-quarter from -$26000.0 in Q2 2016, and down 243.2% on a YoY basis from $1.2 million in Q4 2015.
Novavax (NVAX) Change in Receivables (2010 - 2016) Analysis & Trends
Novavax's Change in Receivables history runs 7 years deep, the most recent figure standing at -$1.7 million for Q3 2016.
- In Q3 2016, Change in Receivables fell 243.2% year-over-year to -$1.7 million; the TTM figure through Sep 2016 stood at -$5.7 million (down 55.73% YoY), while the FY2021 annual figure was -$144.4 million, up 41.25% from the prior year.
- Change in Receivables was -$1.7 million for Q3 2016 at Novavax, down from -$26000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $2.8 million in Q4 2014 to a low of -$6.0 million in Q2 2015.
- Historically, Change in Receivables has averaged -$464894.7 across 5 years, with a median of -$240000.0 in 2012.
- The sharpest annual moves came in 2014 and 2016: Change in Receivables surged 1661.25% in 2014, then sank 2569.23% in 2016.
- A 5-year view of Change in Receivables shows it stood at -$1.5 million in 2012, then surged by 110.97% to $160000.0 in 2013, then soared by 1661.25% to $2.8 million in 2014, then slumped by 171.43% to -$2.0 million in 2015, then gained by 14.75% to -$1.7 million in 2016.
- The last three Change in Receivables figures came in at -$1.7 million (Q3 2016), -$26000.0 (Q2 2016), and -$1.9 million (Q1 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | -1.72 Mn |
| Sep 30, 2016 | -1.72 Mn |
| Jun 30, 2016 | -26,000.00 |
| Jun 30, 2016 | -26,000.00 |
| Mar 31, 2016 | -1.93 Mn |
| Mar 31, 2016 | -1.93 Mn |
| Dec 31, 2015 | -2.01 Mn |
| Dec 31, 2015 | -2.01 Mn |
| Sep 30, 2015 | -500,000.00 |
| Sep 30, 2015 | -500,000.00 |
| Jun 30, 2015 | -6.04 Mn |
| Jun 30, 2015 | -6.04 Mn |
| Mar 31, 2015 | 78,000.00 |
| Mar 31, 2015 | 78,000.00 |
| Dec 31, 2014 | 2.82 Mn |
| Dec 31, 2014 | 2.82 Mn |
| Sep 30, 2014 | -829,000.00 |
| Sep 30, 2014 | -829,000.00 |
| Jun 30, 2014 | -731,000.00 |
| Jun 30, 2014 | -731,000.00 |